Rationale, baseline characteristics and methodology of the non-interventional VIVA study in postmenopausal osteoporosis

Journal: Osteologie
ISSN: 1019-1291


Issue: Issues of 2014 (Vol. 23): Issue 1 2014 (1-72)
Pages: 49-55

Rationale, baseline characteristics and methodology of the non-interventional VIVA study in postmenopausal osteoporosis

P. Hadji (1), L. C. Hofbauer (2), D. Felsenberg (3), M. Amling (4), A. Kurth (5)

(1) Philipps University of Marburg, Department of Gynaecology, Reproductive Medicine and Osteoporosis, Marburg, Germany; (2) Division of Endocrinology, Diabetes and Bone Metabolic Disorders, University Medical Center, Technical University Dresden, Dresden, Germany; (3) Charité University Medicine Berlin, Campus Benjamin Franklin, Center for Muscle and Bone Research, Berlin, Germany; (4) University Hospital Hamburg-Eppendorf, Hamburg, Germany; (5) Specialty hospital Ratingen, Centre for Orthopaedics and Rheumatology, Ratingen, Germany


Osteoporosis, fracture, compliance, alendronate, ibandronate


Background: It is important to understand compliance and persistence with medication use in the clinical practice of osteoporosis treatment. The purpose of this work is to describe the “intravenous ibandronate versus oral alendronate” (VIVA) study, a non-interventional trial to assess the compliance and persistence of osteopenic post-menopausal women with treatment via weekly oral alendronate or intravenous ibandronate (Bonviva®) every three months. Methods: 4477 patients receiving ibandronate 3 mg i. v. quarterly and 1491 patients receiving alendronate 70 mg orally weekly were included in the study. Matched pairs of 901 subjects in each group were also generated. Matching was performed on the basis of age, body mass index, fracture history at study inclusion, prior treatment with bisphosphonates and the number of concomitant disorders. Secondary outcome measures of osteoporosis related fractures, mobility restriction and pain, analgesia, quality of life questionnaires as well as attitudes to medications were assessed. The primary outcome parameters of compliance and persistence will be tracked in these subjects. Results: At baseline, the entire collectives differed significantly on body weight (less in ibandronate group), duration since osteoporosis diagnosis (longer in ibandronate), and incidence of prior osteoporotic fracture (higher in ibandronate group). The matched-pairs differed only on mobility restriction and quality of life (both worse in ibandronate group). Conclusion: The results from the VIVA study trial will provide scientific rationale for clinical recommendations in the pharmacological treatment of postmenopausal osteoporosis.

You may also be interested in...

R. Bergner

arthritis + rheuma 2007 27 6: 335-339


T. Tuncel (1), M. Bode (1), K. M. Peters (1)

Osteologie 2017 26 2: 100-104

International experience

P. J. Mitchell (1), D. B. Lee (2)

Osteologie 2014 23 1: 39-44